Organization (Academic)
Aix-Marseille Université
ClinicalTrials.gov lists Aix-Marseille Université as lead sponsor of 709 trials, counting the companies grouped under it. Aix-Marseille Université itself has 1 active development program.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.0 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo Université d'Aix-Marseille, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Aix-Marseille Université and 2 companies grouped under it: 709 lead-sponsored trials (7 its own, 702 in the grouped companies) and 3 legal-entity registrations (1 its own, 2 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Assistance Publique Hôpitaux de Marseille | 700 | 1 |
| Hôpital de la Timone | 2 | 1 |
Disease areas (334)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Epilepsy | 22 |
| Diabetes Mellitus | 16 |
| Inflammation | 11 |
| Lung Neoplasms | 11 |
| Parkinson Disease | 11 |
Showing 5 of 334 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 3 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 2 |
| 2017 | 2 |
| 2016 | 4 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Propolis | Insulin Resistance | Not reported | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 1 hit target (n=1) | 0 of 1 on time (n=1) |
Journals published in (242)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Trials | 14 |
| PloS one | 13 |
| The New England journal of medicine | 10 |
| JAMA | 9 |
| BMJ open | 7 |
Showing 5 of 242 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 251 | 77 | 2025-12-16 |
Organization relationships (111)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Assistance Publique – Hôpitaux de Paris | Co sponsors trial with | 12 |
| Centre Hospitalier Universitaire de Nice | Co sponsors trial with | 7 |
| Nantes University Hospital | Co sponsors trial with | 5 |
| University Hospital, Toulouse | Co sponsors trial with | 5 |
| Centre Hospitalier Universitaire de Saint Etienne | Co sponsors trial with | 3 |
Showing 5 of 111 relationships.
Latest dated events (1,036)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,036 events.
Biomarker capability evidence (10)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ERCC8 | Trial collaborator | Named in trial inclusion criteria |
| STXBP1 | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial exclusion criteria |
| F3 | Trial collaborator | Named in trial exclusion criteria |
| OSR1 | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 10 evidence rows.
Biomarkers this organization publishes on (1,565)
Shown in this order: most publications first.
Showing 5 of 1,565 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, approved assets, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.